查詢結果分析
相關文獻
- Analysis of First Year Mortality in Stage Ⅲ Esophageal Cancer Patients Treated with Concurrent Chemoradiotherapy
- 粗製巴斯德桿菌D型毒素誘發腫瘤壞死因子-α產生與豬萎縮性鼻炎關係之探討
- p53 Gene Alternation in Squamous Cell Carcinoma of the Esophagus Detected by PCR-Cold SSCP Analysis
- Detection of Tumor Necrosis Factor-α and Receptors in the Serum and Synovial Fluid of Patients With Rheumatoid Arthritis and Osteoarthritis
- 第一型介白質受體對抗劑和腫瘤壞死因子結合蛋白對去卵巢後骨質減少的效果
- Clinical Application of Ultrasonic Mini-Probes in Esophageal Cancer: The Experience of Ntuh
- Excessive Expression of the Tumor Necrosis Factor-α Gene in the Kidneys of Patients with Membranous Glomerulonephritis
- 飼糧中添加吡啶甲酸鉻對豬隻週邊血液單核細胞於體外分泌白血球中介質-2和注射脂多醣之生理反應
- Effects of IL-1β and TNF-α on DNA and Protein Synthesis in Cultured Human Dental Pulp Cells
- 一所教學醫院的死因診斷形式錯誤及準確度分析
頁籤選單縮合
題 名 | Analysis of First Year Mortality in Stage Ⅲ Esophageal Cancer Patients Treated with Concurrent Chemoradiotherapy=第三期食道癌患者經同步化放療後的第一年死亡分析 |
---|---|
作 者 | 黃彥閔; 王正旭; 黃仁聖; 蔡介生; 陳子平; 葉光揚; 藍以政; 吳宗翰; 張沛弘; 張悅詩; 賴建宏; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 29:3 2013.09[民102.09] |
頁 次 | 頁122-130 |
分類號 | 416.216 |
關鍵詞 | 食道癌; 同步化放療; 死因; Esophageal cancer; Concurrent chemoradiotherapy; Cause of death; |
語 文 | 英文(English) |
中文摘要 | 局部晚期食道癌的治療包括手術、放射治療、以及化學治療,多數患者接受跨領域 之間的合併治療。在台灣食道癌在診斷後第一年的存活率不到五成,代表許多患者可能 在尚未接受治療、治療中、及治療結束後的近期內死亡,了解第一年內的死亡原因相形 重要。本研究根據 AJCC 第七版分期,分析 47 例曾接受同步化放療的第三期食道癌患者, 在診斷後第一年內死亡的 18 個案例。其中 10 例 (56%) 有腫瘤惡化,多為遠處轉移;13 例 (72%) 直接死因為感染,1 例 (6%) 為食道大動脈瘻管,1 例 (6%) 為食道縱膈腔瘻 管,1 例 (6%) 為疾病惡化,1 例 (6%) 為社會案件,1 例 (6%) 為腦梗塞。未來需要更 多的研究分析同步化放療後早期的死亡及併發症以改善食道癌的治療成果。 |
英文摘要 | Medical practitioners currently have several management options to treat locally advanced esophageal cancer, including surgery, radiation therapy, and chemotherapy. However, most patients had multidisciplinary treatment. In Taiwan, the one-year survival rate of esophageal cancer was less than 50%. This phenomenon may be due to patient mortality before therapy, during therapy, or early after the completion of therapy. Because of this elevated mortality rate, it is important to illustrate the cause of mortality in the first year. We analyzed 47 locally advanced stage III esophageal cancer patients who had received concurrent chemoradiotherapy (CCRT) in our hospital. Eighteen of them died in the first year after diagnosis. Ten patients (56%) had tumor progression (primarily distant metastasis), 13 patients (72%) died directly from infection, 1 patient (6%) died from main artery esophageal fistula, 1 patient (6%) died from esophageal mediastinal fistula, 1 patient (6%) died solely from disease progression, 1 patient (6%) died from some kind of social event, and 1 patient (6%) died from ischemic stroke. Timely research to analyze the complications and mortality early after CCRT is relevant to improving treatment outcomes. |
本系統中英文摘要資訊取自各篇刊載內容。